Cardiome Pharma
Vancouver
About Cardiome Pharma
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $57.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jun 2016)
- Ticker: nasdaq:CRME
- Website: cardiome.com
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/cardiome-pharma-2236239 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.